There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on OrganiGram Holdings (OGI – Research Report) and Plus Therapeutics (PSTV – Research Report) with bullish sentiments.
OrganiGram Holdings (OGI)
Jefferies analyst Owen Bennett maintained a Buy rating on OrganiGram Holdings today and set a price target of C$4.35. The company’s shares closed last Friday at $2.01.
According to TipRanks.com, Bennett has 0 stars on 0-5 stars ranking scale with an average return of
OrganiGram Holdings has an analyst consensus of Strong Buy, with a price target consensus of $3.14, representing a 50.2% upside. In a report issued on May 15, Canaccord Genuity also maintained a Buy rating on the stock with a C$3.25 price target.
See Insiders’ Hot Stocks on TipRanks >>
Plus Therapeutics (PSTV)
JonesTrading analyst Justin Walsh reiterated a Buy rating on Plus Therapeutics today and set a price target of $32.00. The company’s shares closed last Friday at $2.19.
According to TipRanks.com, Walsh is a 3-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Plus Therapeutics with a $18.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on OGI:
- Here’s What You Missed in Cannabis, Psychedelics This Week
- OrganiGram Unveils Q2 Fiscal 2024 Financial Insights
- Options Volatility and Implied Earnings Moves Today, May 14, 2024
- Organigram’s Strong Q2 Growth and Strategic Moves
- Options Volatility and Implied Earnings Moves This Week, May 13 – May 16, 2024
